DPP4 and type 2 diabetes mellitus: A considerable proportion of our study population (34%) suffered from type 2 diabetes, a condition in which plasma DPP4 activity is altered (Mannucci et al., 2005; McKillop et al., 2008) and DPP4 inhibitors are commonly used oral antidiabetics.